Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00413764
Recruitment Status : Completed
First Posted : December 20, 2006
Last Update Posted : April 10, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Tibolone has been registered for treatment of menopausal symptoms. It is, however, not known what the effects are of tibolone in postmenopausal women diagnosed with sexual dysfunction. This is important because there is currently no approved treatment of libido problems in postmenopausal women. Therefore, the primary aim of this study was to compare the effects of tibolone with an estrogen/progestogen skin patch in postmenopausal women diagnosed sexual dysfunction.

Condition or disease Intervention/treatment Phase
Sexual Dysfunction Drug: tibolone Drug: estradiol-norethisterone Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 358 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Double Dummy Trial to Compare the Effects Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on Sexual Desire and Arousal in Postmenopausal Women With Sexual Dysfunction
Actual Study Start Date : March 23, 2004
Actual Primary Completion Date : November 15, 2005
Actual Study Completion Date : November 15, 2005

Arm Intervention/treatment
Experimental: 1
Drug: tibolone
tibolone (2.5 mg) over 24 weeks
Other Name: Livial®

Active Comparator: 2
transdermal continuous combined E2-NETA (estradiol-norethisterone)
Drug: estradiol-norethisterone
transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
Other Names:
  • Combipatch®
  • Estalis®

Primary Outcome Measures :
  1. Compare the effect of tibolone (2.5 mg) to transdermal E2/NETA (50/140 mcg) on the vaginal bleeding and spotting rate in healthy postmenopausal women with sexual dysfunction. [ Time Frame: Week 13-24 of the in treatment period ]
  2. Compare the effect of tibolone to E2/NETA on sexual functioning in healthy postmenopausal women with sexual dysfunction. [ Time Frame: Week 8-12 and Week 20-24 of the in-treatment period. ]

Secondary Outcome Measures :
  1. Compare the effects of tibolone to E2/NETA on the frequency of satisfactory sexual events, the frequency of sexual fantasies and subjective arousal, scores on the FSFI, FSDS, WHQ and endocrine parameters [ Time Frame: Week 8-12 and Week 20-24 of the in-treatment period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   48 Years to 68 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Physically and mentally healthy postmenopausal women, >=48 and <=68 years of age, with an intact uterus.
  • Women were to suffer from decreased satisfactory sexual activity compared to younger age and sexual problems were not to be considered caused by relationship/partner problems. The decreased sexual functioning was to result in sexually related personal distress as confirmed by the FSDS (score =15).
  • An affirmative answer was to be given to the following questions: (a) In previous years did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend?
  • All subjects were to have an established sexual relationship of at least 6 months duration prior to screening.
  • Women were to be sexually active.
  • Normal mammography within 6 months prior to randomization.
  • Body mass index >18 and <=32 kg/m2.
  • Voluntary written informed consent

Exclusion Criteria:

  • Any unexplained abnormal uterine bleeding
  • Double layer endometrial thickness >4 mm
  • Tibolone or transdermal E2/NETA use within 3 months prior to screening
  • Progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening
  • Use of intra-uterine progestogen
  • Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity
  • Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening
  • Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed)
  • Use of anti -androgens within the preceding 5 years prior to screening.
  • Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction
  • Women who had early onset sexual dysfunction (>15 years prior to menopause)
  • Women suffering from androgenic alopecia, acne or hirsutism
  • Women suffering from illnesses influencing sexuality
  • Women using medication influencing sexuality
  • Moderate to severe depression
  • Current or prior use of antidepressant within 8 weeks prior to screening
  • Major gynecological surgery in the preceding 3 months
  • Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed)
  • History or presence of severe psychiatric illness and/or any addictions to drugs, medication or alcohol in the past 3 years
  • Diseases for which exogenous hormonal steroids were contraindicated.
  • History or presence of any malignancy, except successfully treated non-melanoma skin cancers
  • History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders
  • History or presence of liver, gallbladder or renal disease, epilepsy or classical migraine headaches
  • Uncontrolled hypertension
  • Women with abnormal cervical smear results
  • History or presence of breast cancer, suspicious breast lump or mammographic abnormality
  • Known hypersensitivity to any of the ingredients of the trial medication.
  • Non-compliance with the screening diary
  • Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts
  • Drugs known to interfere with the pharmacokinetics of the steroids
  • Use of investigational drugs within the past 60 days
  • Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well being during the course of the trial

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00413764     History of Changes
Other Study ID Numbers: P06089
First Posted: December 20, 2006    Key Record Dates
Last Update Posted: April 10, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Contraceptive Agents, Female
Polyestradiol phosphate
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Norethindrone acetate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Androgen Antagonists
Hormone Antagonists
Antihypertensive Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Modulators
Anabolic Agents
Contraceptives, Oral, Synthetic
Contraceptives, Oral